Background: Radiotherapy treatment for cervical cancer (CC) often induces side effects, including inflammation, dryness, dyspareunia. Considering its key role in the healing process, hyaluronic acid (HA) could be useful for the completion of radiotherapy. Objectives: The aim of this work was to evaluate the ability of HA to reduce the onset of side effects due to radiotherapy. Materials and Methods: In total, 180 women undergoing radiotherapy were randomized into two arms: Controls and those treated with vaginal suppositories containing low-molecular-weight HA from day 1 of radiotherapy. The study lasted 5 weeks and was characterized by three visits: At baseline (T0), 15 days later (T1), and at the end of the radiotherapy cycle (T2). The onset of side effects, pain, safety, efficacy, acceptability of treatment, and compliance to the therapy were evaluated. Results: Patients in the control arm reported the onset and worsening of all symptoms with a moderate or severe grade at T2, whereas in the treatment arm almost 90% of patients reported the absence of symptoms or a mild grade. All patients in the treatment arm referred a lower intensity of pain on a visual analog scale compared with the control arm at T2 (6.85 ± 0.94 vs. 1.88 ± 1.02). Conclusions: HA was able to help vaginal mucosa healing during radiotherapy in patients with CC
Clinical evaluation of low-molecular-weight hyaluronic acid-based treatment on onset of acute side effects in women receiving adjuvant radiotherapy after cervical surgery: A randomized clinical trial
Delia, Pietro
Primo
;Pontoriero, Antonio;Iati, Giuseppe;Pergolizzi, StefanoUltimo
2019-01-01
Abstract
Background: Radiotherapy treatment for cervical cancer (CC) often induces side effects, including inflammation, dryness, dyspareunia. Considering its key role in the healing process, hyaluronic acid (HA) could be useful for the completion of radiotherapy. Objectives: The aim of this work was to evaluate the ability of HA to reduce the onset of side effects due to radiotherapy. Materials and Methods: In total, 180 women undergoing radiotherapy were randomized into two arms: Controls and those treated with vaginal suppositories containing low-molecular-weight HA from day 1 of radiotherapy. The study lasted 5 weeks and was characterized by three visits: At baseline (T0), 15 days later (T1), and at the end of the radiotherapy cycle (T2). The onset of side effects, pain, safety, efficacy, acceptability of treatment, and compliance to the therapy were evaluated. Results: Patients in the control arm reported the onset and worsening of all symptoms with a moderate or severe grade at T2, whereas in the treatment arm almost 90% of patients reported the absence of symptoms or a mild grade. All patients in the treatment arm referred a lower intensity of pain on a visual analog scale compared with the control arm at T2 (6.85 ± 0.94 vs. 1.88 ± 1.02). Conclusions: HA was able to help vaginal mucosa healing during radiotherapy in patients with CCFile | Dimensione | Formato | |
---|---|---|---|
Clinical Evaluation of Low_Molecular_Weight Delia P.pdf
solo utenti autorizzati
Descrizione: Articolo - First online
Tipologia:
Versione Editoriale (PDF)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
147.17 kB
Formato
Adobe PDF
|
147.17 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Clinical Evaluation of Low-Molecular-Weight.pdf
solo utenti autorizzati
Descrizione: Articolo principale - Edizione definitiva
Tipologia:
Versione Editoriale (PDF)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
186.97 kB
Formato
Adobe PDF
|
186.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.